Detalhe da pesquisa
1.
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).
Breast Cancer Res Treat
; 189(1): 103-110, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34120223
2.
Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.
Ann Surg Oncol
; 24(11): 3116-3123, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28699130
3.
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.
Breast Cancer Res Treat
; 146(3): 557-66, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25001612
4.
Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort.
Ann Surg Oncol
; 20(10): 3254-8, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23975317
5.
Individual responses to chemotherapy-induced oxidative stress.
Breast Cancer Res Treat
; 125(2): 583-9, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20830514
6.
Pseudoangiomatous stromal hyperplasia (PASH) causing massive breast enlargement: MRI findings.
Breast J
; 18(6): 600-1, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-23110315
7.
Synchronous primary carcinoma of breast and ovary versus ovarian metastases.
Semin Oncol
; 42(2): e13-24, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25843740
8.
Testing for hereditary breast and ovarian cancer in the southeastern United States.
Ann Surg
; 231(5): 624-34, 2000 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-10767783